Alvotech (ALVO) Tax Expense: History & Chart

Alvotech(ALVO)

Drug Manufacturers - Specialty & Generic · Luxembourg, LU

$6.08-0.04 (-0.57%)

Delayed quote: Oct 6, 2026, 11:00 AM EDT

About Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. Similarly, AVT04 is a biosimilar version of Stelara, targeting inflammatory conditions such as psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. For ophthalmic conditions, AVT06 serves as a biosimilar to Eylea, intended for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy. Currently in preclinical stages, AVT03 is a biosimilar to Xgeva and Prolia, with the goal of preventing bone fractures, alleviating spinal cord compression, reducing the necessity for radiation or bone surgery in certain cancer patients, and both preventing bone loss and increasing bone density. Additionally, Alvotech's pipeline features AVT05, an early-stage biosimilar for Simponi and Simponi Aria, which is being developed for various inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Other promising candidates include AVT16, an immunology biosimilar; AVT23, a late-stage biosimilar to Xolair, aimed at treating nasal polyps; and AVT33, an oncology biosimilar. Established in 2013, Alvotech maintains its primary corporate headquarters in Reykjavik, Iceland.

Luxembourg, LU

1,279 employees

www.alvotech.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Lisa Graver

View full financials

Income Tax Expense

The latest quarterly tax expense is $59.00 Thousand. Income tax expense is the amount a company pays in federal, state, and foreign income taxes based on its taxable income for the period.

Q2 FY2026 (2026-06-30).

EBT|Net Income|Free Cash Flow|Revenue|Income Statement

Tax Expense

ALVO Tax Expense

$59000.00

Reported quarterly tax expense; no daily interpolation. Q2 FY2026 (2026-06-30): $59000.00.

-51.93% over 10Y

Current Tax Expense

$59.00K

$59.00 Thousand

Q2 FY2026 · 2026-06-30

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly Tax Expense History

Period	Tax Expense	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$59.00K	N/A	N/A
Q1 FY2026Period end 2026-03-31	−$44.00K	N/A	+99.73%
Q4 FY2025Period end 2025-12-31	$148.23M	N/A	+558.04%
Q3 FY2025Period end 2025-09-30	−$813.00K	+96.42%	+93.91%
Q2 FY2025Period end 2025-06-30	−$22.73M	-39.79%	N/A
Q1 FY2025Period end 2025-03-31	−$16.26M	N/A	-152.55%
Q4 FY2024Period end 2024-12-31	$22.53M	N/A	N/A
Q3 FY2024Period end 2024-09-30	−$13.36M	N/A	N/A
Q2 FY2024Period end 2024-06-30	$11.57M	N/A	N/A
Q1 FY2024Period end 2024-03-31	−$6.44M	+80.03%	N/A
Q4 FY2023Period end 2023-12-31	−$32.24M	N/A	N/A
Q3 FY2023Period end 2023-08-31	−$17.22M	N/A	N/A
Q2 FY2023Period end 2023-06-30	−$20.47M	+30.31%	N/A
Q1 FY2023Period end 2023-03-31	−$29.38M	-26.12%	-61.79%
Q4 FY2022Period end 2022-12-31	−$23.30M	N/A	N/A
Q3 FY2022Period end 2022-09-30	$2.30M	N/A	N/A
Q2 FY2022Period end 2022-06-30	$1.09M	N/A	N/A
Q1 FY2022Period end 2022-03-31	−$18.16M	N/A	-40.13%
Q4 FY2021Period end 2021-12-31	$261.00K	N/A	N/A
Q3 FY2021Period end 2021-09-30	−$22.04M	-70.05%	+27.58%
Q2 FY2021Period end 2021-06-30	−$12.96M	0.00%	+57.42%
Q1 FY2021Period end 2021-03-31	−$12.96M	+57.42%	+57.42%
Q4 FY2020Period end 2020-12-31	−$30.43M	0.00%	N/A
Q3 FY2020Period end 2020-09-30	−$30.43M	0.00%	N/A
Q2 FY2020Period end 2020-06-30	−$30.43M	0.00%	N/A
Q1 FY2020Period end 2020-03-31	−$30.43M	N/A	N/A
Q4 FY2019Period end 2019-12-31	$122.75K	N/A	N/A
Q3 FY2019Period end 2019-09-30	$122.75K	N/A	N/A
Q2 FY2019Period end 2019-06-30	$122.75K	N/A	N/A
Q1 FY2019Period end 2019-03-31	$122.75K	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 30, 2026